Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36083   clinical trials with a EudraCT protocol, of which   5932   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER]

    Summary
    EudraCT number
    2009-016675-29
    Trial protocol
    GB  
    Global end of trial date
    29 Feb 2016

    Results information
    Results version number
    v1(current)
    This version publication date
    07 Apr 2017
    First version publication date
    07 Apr 2017
    Other versions
    Summary report(s)
    Journal Article

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    RC200902
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01512186
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Queen Mary University London
    Sponsor organisation address
    5 Walden Street, London, United Kingdom, E1 2EF
    Public contact
    Thomas Powles, Centre for Experimental Cancer Medicine, bci-panther@qmul.ac.uk
    Scientific contact
    Thomas Powles, Centre for Experimental Cancer Medicine, bci-panther@qmul.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    09 Dec 2015
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Feb 2016
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To determine the clinical benefit of giving 14 weeks pazopanib to patients with metastatic kidney cancer prior to surgery to remove the cancerous kidney (nephrectomy).
    Protection of trial subjects
    Patients were closely monitored as part of the clinical trial. Pazopanib was chosen as having a good effect in renal cancer, but with a lower toxicity profile than the similar, licensed, drug, sunitinib. Therefore the effect of the drug was well known, and the trial was looking at the effect on the surgery. The additional scans given as part of the trial were reassuring for the patients also.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    06 Jul 2010
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 104
    Worldwide total number of subjects
    104
    EEA total number of subjects
    104
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    48
    From 65 to 84 years
    45
    85 years and over
    11

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Between 6th July 2010 and 9 Dec 2015, 104 previously untreated patients with metastatic clear cell renal cancer were recruited to the PANTHER trial. This was a multicentre single-arm trial enrolling from 12 centres in the United Kingdom with nephrectomy services.

    Pre-assignment
    Screening details
    111 patients were screened for the trial, with 7 patients being ineligible.

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Arm title
    Pazopanib
    Arm description
    intervention arm (single)
    Arm type
    single

    Investigational medicinal product name
    Pazopanib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    800mg PO OD (2 x 400mg tablets)

    Number of subjects in period 1
    Pazopanib
    Started
    104
    Completed
    104

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial (overall period)
    Reporting group description
    Overall trial

    Reporting group values
    Overall trial (overall period) Total
    Number of subjects
    104 104
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    48 48
        From 65-84 years
    45 45
        85 years and over
    0 0
        missing
    11 11
    Age continuous
    Units: years
        median (inter-quartile range (Q1-Q3))
    63.8 (56.3 to 70.8) -
    Gender categorical
    Units: Subjects
        Female
    24 24
        Male
    80 80
        not recorded
    0 0
    MSKCC prognostic risk
    Memorial Sloan Kettering Cancer Center score
    Units: Subjects
        Good
    0 0
        Intermediate
    83 83
        Poor
    18 18
        not recorded
    3 3
    Performance status
    Units: Subjects
        Grade 0
    29 29
        Grade 1
    63 63
        Grade 2
    9 9
        not recorded
    3 3
    Type of surgery
    Units: Subjects
        Open
    43 43
        Laparoscopic
    18 18
        Complete
    1 1
        Partial
    1 1
        none
    41 41
    T-stage at nephrectomy
    Units: Subjects
        T1
    6 6
        T2
    7 7
        T3
    41 41
        T4
    6 6
        no nephrectomy
    41 41
        Not recorded
    3 3
    Lung metastasis
    Units: Subjects
        yes
    90 90
        no
    14 14
    Bone metastasis
    Units: Subjects
        yes
    29 29
        no
    75 75
    Lymph node metastasis
    Units: Subjects
        yes
    48 48
        no
    56 56
    Liver metastasis
    Units: Subjects
        yes
    15 15
        no
    89 89
    Radiologic T stage at diagnosis
    Units: Subjects
        T1
    10 10
        T2
    29 29
        T3
    52 52
        T4
    11 11
        Not recorded
    2 2
    Primary tumour size
    Units: cm
        median (inter-quartile range (Q1-Q3))
    10 (8.3 to 11.6) -
    Subject analysis sets

    Subject analysis set title
    Pazopanib
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All subjects

    Subject analysis set title
    clinical benefit
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Patients assessable for clinical benefit prior to planned nephrectomy. Four patients were not assessable.

    Subject analysis sets values
    Pazopanib clinical benefit
    Number of subjects
    104
    100
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    48
        From 65-84 years
    45
        85 years and over
    0
        missing
    11
    Age continuous
    Units: years
        median (inter-quartile range (Q1-Q3))
    63.8 (56.3 to 70.8)
    Gender categorical
    Units: Subjects
        Female
    24
        Male
    80
        not recorded
    0
    MSKCC prognostic risk
    Memorial Sloan Kettering Cancer Center score
    Units: Subjects
        Good
    0
        Intermediate
    83
        Poor
    18
        not recorded
    3
    Performance status
    Units: Subjects
        Grade 0
    29
        Grade 1
    63
        Grade 2
    9
        not recorded
    3
    Type of surgery
    Units: Subjects
        Open
    43
        Laparoscopic
    18
        Complete
    1
        Partial
    1
        none
    41
    T-stage at nephrectomy
    Units: Subjects
        T1
    6
        T2
    7
        T3
    41
        T4
    6
        no nephrectomy
    41
        Not recorded
    3
    Lung metastasis
    Units: Subjects
        yes
    90
        no
    14
    Bone metastasis
    Units: Subjects
        yes
    29
        no
    75
    Lymph node metastasis
    Units: Subjects
        yes
    48
        no
    56
    Liver metastasis
    Units: Subjects
        yes
    15
        no
    89
    Radiologic T stage at diagnosis
    Units: Subjects
        T1
    10
        T2
    29
        T3
    52
        T4
    11
        Not recorded
    2
    Primary tumour size
    Units: cm
        median (inter-quartile range (Q1-Q3))
    10 (8.3 to 11.6)
    10 (8.3 to 11.6)

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Pazopanib
    Reporting group description
    intervention arm (single)

    Subject analysis set title
    Pazopanib
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All subjects

    Subject analysis set title
    clinical benefit
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Patients assessable for clinical benefit prior to planned nephrectomy. Four patients were not assessable.

    Primary: Clinical benefit

    Close Top of page
    End point title
    Clinical benefit
    End point description
    Percentage of patients who obtained clinical benefit at 14 weeks.
    End point type
    Primary
    End point timeframe
    overall trial
    End point values
    Pazopanib clinical benefit
    Number of subjects analysed
    100
    100
    Units: rate
        number (confidence interval 95%)
    0.84 (0.75 to 0.91)
    0.84 (0.75 to 0.91)
    Statistical analysis title
    Clinical benefit
    Statistical analysis description
    number of patients that achieved clinical benefit
    Comparison groups
    Pazopanib v clinical benefit
    Number of subjects included in analysis
    200
    Analysis specification
    Pre-specified
    Analysis type
    other [1]
    Method
    Parameter type
    rate
    Point estimate
    0.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.75
         upper limit
    0.91
    Notes
    [1] - this analysis does compare two groups, only estimates the overall clinical benefit in the 'clinical benefit' group

    Secondary: Progression-free survival

    Close Top of page
    End point title
    Progression-free survival
    End point description
    End point type
    Secondary
    End point timeframe
    Date of randomisation until disease progression or death from any cause.
    End point values
    Pazopanib Pazopanib
    Number of subjects analysed
    104
    104
    Units: months
        median (confidence interval 95%)
    7.1 (6 to 9.2)
    7.1 (6 to 9.2)
    No statistical analyses for this end point

    Secondary: Overall survival

    Close Top of page
    End point title
    Overall survival
    End point description
    End point type
    Secondary
    End point timeframe
    Date of randomisation until death from any cause
    End point values
    Pazopanib Pazopanib
    Number of subjects analysed
    104
    104
    Units: months
        median (confidence interval 95%)
    22.7 (14.3 to 99999999)
    22.7 (14.3 to 99999999)
    No statistical analyses for this end point

    Secondary: Surgical complication

    Close Top of page
    End point title
    Surgical complication
    End point description
    End point type
    Secondary
    End point timeframe
    Surgery complications observed from nephrectomy
    End point values
    Pazopanib Pazopanib
    Number of subjects analysed
    63
    63
    Units: Number of patients
    number (not applicable)
        Bleeding
    5
    5
        Delayed wound healing
    4
    4
        Splenectomy
    2
    2
        Elevated creatinine level
    1
    1
    Attachments
    Untitled (Filename: Nephrectomy data Table 1.docx)
    No statistical analyses for this end point

    Secondary: Response to pazopanib treatment

    Close Top of page
    End point title
    Response to pazopanib treatment
    End point description
    Median size of primary tumour before and after pazopanib treatment
    End point type
    Secondary
    End point timeframe
    Length of pazopanib treatment
    End point values
    Pazopanib Pazopanib
    Number of subjects analysed
    104
    104
    Units: cm
    number (not applicable)
        Before Pazopanib
    10
    10
        After pazopanib
    8.3
    8.3
    Attachments
    Percentage Change of Primary Tumour
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Overall trial (overall period)
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    CTC
    Dictionary version
    3.0
    Reporting groups
    Reporting group title
    Pazopanib
    Reporting group description
    -

    Serious adverse events
    Pazopanib
    Total subjects affected by serious adverse events
         subjects affected / exposed
    67 / 104 (64.42%)
         number of deaths (all causes)
    52
         number of deaths resulting from adverse events
    Vascular disorders
    Vascular disorders
         subjects affected / exposed
    4 / 104 (3.85%)
         occurrences causally related to treatment / all
    3 / 4
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    General disorders and administration site conditions
         subjects affected / exposed
    8 / 104 (7.69%)
         occurrences causally related to treatment / all
    1 / 10
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Psychiatric disorders
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Reproductive system and breast disorders
    Reproductive system and breast disorders
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Injury, poisoning and procedural complications
         subjects affected / exposed
    12 / 104 (11.54%)
         occurrences causally related to treatment / all
    3 / 13
         deaths causally related to treatment / all
    0 / 2
    Investigations
    Investigations
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Cardiac disorders
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Respiratory, thoracic and mediastinal disorders
         subjects affected / exposed
    11 / 104 (10.58%)
         occurrences causally related to treatment / all
    1 / 13
         deaths causally related to treatment / all
    0 / 2
    Blood and lymphatic system disorders
    Blood and lymphatic system disorders
         subjects affected / exposed
    5 / 104 (4.81%)
         occurrences causally related to treatment / all
    3 / 6
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Nervous system disorders
         subjects affected / exposed
    4 / 104 (3.85%)
         occurrences causally related to treatment / all
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Gastrointestinal disorders
         subjects affected / exposed
    15 / 104 (14.42%)
         occurrences causally related to treatment / all
    8 / 19
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Renal and Urinary disorders
         subjects affected / exposed
    9 / 104 (8.65%)
         occurrences causally related to treatment / all
    1 / 10
         deaths causally related to treatment / all
    0 / 1
    Skin and subcutaneous tissue disorders
    Skin and subcutaneous tissue disorders
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Musculoskeletal and connective tissue disorders
    Musculoskeletal and connective tissue disorders
         subjects affected / exposed
    4 / 104 (3.85%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Metabolism and nutrition disorders
         subjects affected / exposed
    6 / 104 (5.77%)
         occurrences causally related to treatment / all
    2 / 6
         deaths causally related to treatment / all
    0 / 1
    Infections and infestations
    Infections and infestations
         subjects affected / exposed
    5 / 104 (4.81%)
         occurrences causally related to treatment / all
    1 / 5
         deaths causally related to treatment / all
    0 / 1
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Pazopanib
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    97 / 104 (93.27%)
    Vascular disorders
    hypertension
         subjects affected / exposed
    52 / 104 (50.00%)
         occurrences all number
    141
    Investigations
    weight loss
         subjects affected / exposed
    10 / 104 (9.62%)
         occurrences all number
    14
    General disorders and administration site conditions
    fatigue
         subjects affected / exposed
    88 / 104 (84.62%)
         occurrences all number
    345
    pain
         subjects affected / exposed
    33 / 104 (31.73%)
         occurrences all number
    87
    Gastrointestinal disorders
    constipation
         subjects affected / exposed
    16 / 104 (15.38%)
         occurrences all number
    29
    diarrhoea
         subjects affected / exposed
    55 / 104 (52.88%)
         occurrences all number
    222
    mucositis
         subjects affected / exposed
    15 / 104 (14.42%)
         occurrences all number
    27
    nausea
         subjects affected / exposed
    47 / 104 (45.19%)
         occurrences all number
    116
    taste change
         subjects affected / exposed
    20 / 104 (19.23%)
         occurrences all number
    41
    vomiting
         subjects affected / exposed
    20 / 104 (19.23%)
         occurrences all number
    39
    Skin and subcutaneous tissue disorders
    hand and foot syndrome
         subjects affected / exposed
    33 / 104 (31.73%)
         occurrences all number
    108
    Musculoskeletal and connective tissue disorders
    cramps
         subjects affected / exposed
    10 / 104 (9.62%)
         occurrences all number
    18
    Metabolism and nutrition disorders
    low appetite
         subjects affected / exposed
    14 / 104 (13.46%)
         occurrences all number
    22

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    06 May 2010
    Addition of a thyroid function check 12-weeks prior to trial entry Expansion of exclusion criteria relating to cardiac function - 'Prolonged QT Interval >480msecs or a history of prolonged QT interval >480msecs' Post-surgery visit timepoints changed from 2,6,12 weeks to 4,8,12 weeks.
    22 Sep 2010
    Change of Principal Investigators only
    06 Sep 2011
    Additional of an exclusion criteria to prohibit patients to take part in the GE-135-009 study entering the PANTHER trial
    04 Apr 2012
    Removal of exclusion criteria prohibiting entry to the GE-135-009 study (this study never commenced). 6 weekly MRI changed to 4-weekly. Typographical error in PIS relating to IMP dosing.
    22 May 2012
    Addition of a central facility only
    19 Aug 2014
    Change of Principal Investigators only
    12 Feb 2015
    Removal of central review from protocol Clarification of end of study definition and analysis timepoints
    04 Feb 2016
    Change of Principal Investigator only

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/27254750
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA